Correction MAR label - Prostatype Genomics establishes subsidiary in the United States
The correction refers to the MAR label. This press release should be without the MAR label.Prostatype Genomics is now establishing a subsidiary in the USA, Prostatype Genomics, Inc., wholly owned 100% by Prostatype Genomics AB. It is an important step in the work towards the American market entry.Prostate cancer is today the second most common form of cancer among American men, and in 2022 it is estimated that almost 270,000 American men will be diagnosed with prostate cancer. A rapid establishment in the American market, together with commercial establishment in Europe, are Prostatype